GlaxoSmithKline PLCGSK:LSE

1,354.5
4.50 / 0.33%
3.39m
10.54 %
0.7097
Latest price in GBXToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Feb 11 2016 12:41 GMT.

Consensus recommendation

As of Feb 06, 2016, the consensus forecast amongst 30 polled investment analysts covering GlaxoSmithKline plc advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Feb 21, 2013. The previous consensus forecast advised that GlaxoSmithKline plc would outperform the market.

Previous recommendations
Last year3 months ago2 months ago4 weeks agoLatest
Mouseover chart recommendation details.
Latest recommendation
Buy2
Outperform6
Hold18
Underperform4
Sell0
No opinion0

Share price forecast

The 24 analysts offering 12 month price targets for GlaxoSmithKline plc have a median target of 1,485, with a high estimate of 1,800 and a low estimate of 1,250. The median estimate represents a 9.27% increase from the last price of 1,359. View Full Financials

High+32.9 %1,800
Med+9.7 %1,485
Low-7.7 %1,250

Dividends

In 2015, GlaxoSmithKline PLC reported a dividend of 0.80 GBP, equaling last years dividend. The 24 analysts covering the company expect dividends of 0.82 GBP for the upcoming fiscal year, an increase of 2.50%. View Full Financials

Div growth (TTM)0.00%
  • Mouseover chart for details.
  • Dividend forecast
  • Quarter 1
  • Quarter 2
  • Quarter 3
  • Quarter 4

Earnings history & estimates

On Feb 03, 2016, GlaxoSmithKline plc reported 4th quarter 2015 earnings of 0.181 per share. This result was in line with the consensus of the 12 analysts following the company and under-performed last year's 4th quarter results by 15.81 %.
The next earnings announcement is expected on Apr 27, 2016. View Full Interim Financials

Average growth rate-1.97 %

GlaxoSmithKline plc reported annual 2015 earnings of 0.757 per share on Feb 03, 2016. View Full Annual Financials

Average growth rate-9.56 %
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement

Revenue

GlaxoSmithKline plc had 4th quarter 2015 revenues of 6.286bn. This bettered the 6.256bn consensus of the 11 analysts covering the company. This was 1.62% above the prior year's 4th quarter results. View Full Interim Financials

Average growth rate+0.57 %

GlaxoSmithKline plc had revenues for the full year 2015 of 23.923bn. This was 3.99% above the prior year's results. View Full Annual Financials

Average growth rate-3.11 %
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.